What are the symptoms of axillary lymphoma and how long can one live

When suffering from lymphoma, many people will worry about various issues, among which the most worrying one is the survival rate. So in order to answer some of the lymphoma disease issues, the author introduces the symptoms of axillary lymphoma, and how long can you live with lymphoma?

The most common first clinical manifestation is superficial lymphadenopathy or the formation of nodules, accounting for about 60% to 70% of all cases. Cervical lymphadenopathy is the most common, accounting for 49.3%, followed by axillary and inguinal lymph nodes, each accounting for 12.9.7%; lymph node masses vary in size, often asymmetric, firm and elastic, and are mostly non-tender. In low-grade malignant lymphoma, lymphadenopathy is mostly dispersed without adhesion. Multiple lymph nodes that are easily movable are invasive or highly invasive. In patients with rapidly progressing lymphoma, lymph nodes often fuse into masses, sometimes adhere to the base and skin, and may have local soft tissue infiltration, compression, and edema.

Corresponding symptoms caused by compression, obstruction or tissue destruction, such as mediastinal and hilar lymph node masses, which can cause chest tightness, chest pain, dyspnea, and superior vena cava compression syndrome. Intra-abdominal mesenteric lymph nodes and retroperitoneal lymph node masses can cause abdominal pain, abdominal mass, intestinal obstruction, ureteral obstruction, hydronephrosis, etc.

The most important thing for lymphoma is to actively treat it, choose a good treatment plan, maintain an optimistic spirit, and build confidence in defeating the disease. Ensuring the quality of life is more important than considering the survival period.

The lymphocyte-predominant type has the best prognosis, with a 5-year survival rate of 94.3%, while the lymphocyte-depleted type has the worst prognosis, with a 5-year survival rate of only 27.4%; the nodular sclerosis and mixed cellular types are in between the two. In the clinical staging of Hodgkin's disease, the 5-year survival rate is 92.5% in stage I, 86.3% in stage II, 69.5% in stage III, and 31.9% in stage IV.

The 6-year survival rate of diffuse lymphocytes is 61% if they are well differentiated, 42% if they are poorly differentiated, and only 30% if they are lymphoblastic lymphoma. The presence or absence of systemic symptoms has less impact on prognosis than HD.